Navigate Fool.com
Will SPPI beat
the market?
Community Rating: 4 Stars: Favorite

7.10 -0.02 (-0.28%)

REAL-TIME: Last trade at

Extended Hours: $7.10 $0.00 (0.00%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $7.13
Previous Close $7.12
Daily Range $7.03 - $7.24
52-Week Range $6.36 - $10.32
Market Cap $465.6M
P/E Ratio -5.20
Dividend (Yield) $0.00 (0.0%)
Volume 642,263
Average Daily Volume 1,269,723
Current FY EPS -$0.77

How do you think SPPI
will perform against the market?

Top SPPI Bull/Bear Pitches


zzlangerhans (< 20)
Submitted January 9, 2014

It looks like I've only got six slots left for CAPS picks and I'm going to blow one of them on Spectrum, a company I've been critical of in the past but could be turning a corner. After several quarte … More

0 Replies Reply Report this Post

pavlos1971 (< 20)
Submitted March 13, 2013

From @adamfeuerstein's tweet: "$SPPI -- What happened? 1) Wholesalers didn't order any Fusilev in Q1 2) Hospital demand for Fusilev fell off cliff due to generics."

0 Replies Reply Report this Post

News & Commentary Rss Feed

A Bad Day for Spectrum Pharmaceuticals' Good News

Spectrum gets a drug approved, and then the share price drops.

Monday’s Top Biotech Stories: Spectrum, Bristol-Myers Squibb, GSK, and Theravance

Spectrum, Bristol-Myers Squibb, GSK, and Theravance are the top biotech stocks to watch this morning.

This Week in Biotech: Allergan Three-Peats in a Bad Way While Agenus Impresses

An early FDA approval, an inhaled therapy being turned away by regulators for a third time, and three positive clinical updates are this week's top biotech stories.

3 Biotech Stocks with Catalysts Incoming: Spectrum, Orexigen, and Avanir

For companies involved in the development of drugs, a PDUFA decision will meaningfully impact their stocks. With this in mind, there are several PDUFA decisions in upcoming months to watch for.

Clinical Winners and Losers: Spectrum Pharmaceuticals and Cytokinetics

Find out which biotech posted the best, and worst, clinical results last week.

3 Under-the-Radar Biotech Stocks You Need to Watch in 2014

Nektar Therapeutics, Omeros, and Spectrum Pharmaceuticals all face off with regulators in key decision dates for their developmental drugs later this year

Is Spectrum Pharmaceuticals, Inc. Blazing the Comeback Trail?

Spectrum Pharmaceuticals has been one of the rare losers in the biopharma sector. That trend may be set to change, however, as the company has set itself up for long-term growth.

Why Thompson Creek Metals, Spectrum Pharmaceuticals, and FactSet Research Systems Tumbled Today

The stock markets moved modestly lower as investors wait for the Fed's decision Wednesday, but bad news sent Thompson Creek Metals down 10%, Spectrum Pharmaceuticals falling 9%, and FactSet Research Systems dropping 6%. What's behind the losses for these stocks? Find out here.

Mid-Afternoon Market Update: Markets Mixed as iRobot Surges

Mid-Day Market Update: U.S. Markets Extend Losses; Hewlett-Packard Shares Rise On Analyst Upgrade

See More SPPI News...





Spectrum Pharmaceuticals, Inc. (SPPI) Description

A biopharmaceutical company that acquires and advances a diversified portfolio of drug candidates, with a focus on oncology, urology and other critical health challenges for which there are few other treatment options. Website: http://www.sppirx.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks